SG&A Spending Patterns: Alkermes plc vs. MorphoSys AG

In the competitive landscape of the pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, Alkermes plc and MorphoSys AG have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses.

A Decade of Insights

From 2014 to 2023, Alkermes plc consistently increased its SG&A expenses, peaking in 2023 with a 245% rise from 2014. This upward trend reflects their aggressive market expansion and investment in administrative capabilities. In contrast, MorphoSys AG, while also increasing its SG&A spending, showed a more volatile pattern, with a significant spike in 2021, marking a 1,960% increase from 2014. This suggests strategic shifts, possibly linked to new product launches or market entries.

Strategic Implications

These spending patterns highlight differing strategic priorities. Alkermes focuses on steady growth, while MorphoSys appears to adapt dynamically to market opportunities. Understanding these trends offers valuable insights into each company's operational strategies and market positioning.